为肝细胞癌武装 GPC3 CAR T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
98.9分
★★★★★
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
工程化 CAR 细胞免疫治疗肝细胞癌：当前障碍、创新策略与未来方向
英文原题：Engineering CAR-based cellular immunotherapy for hepatocellular carcinoma: Current barriers, innovative strategies, and future directions.
研究概要
肝细胞癌（HCC）仍然是全球癌症相关死亡的主要原因之一，这主要是因为大多数患者确诊时已处于晚期，治愈性治疗方案有限。
中文摘要
肝细胞癌（HCC）仍然是全球癌症相关死亡的主要原因之一，这很大程度上是因为大多数患者确诊时已处于晚期，治愈性治疗选择有限。嵌合抗原受体（CAR）T细胞疗法已在多种B细胞和浆细胞恶性肿瘤中产生深度且持久的缓解，并促成了多项监管批准；然而，由于其高度免疫抑制的肿瘤微环境（TME），该疗法在HCC等实体瘤中的临床转化仍面临挑战。本综述讨论了限制基于CAR的细胞疗法在HCC中应用的主要障碍，并批判性评估了旨在改善肿瘤进入、适应性、安全性和持久控制的工程化策略。在CROH及其他领先期刊既往综述的基础上，我们提供了一个针对HCC的、从机制到设计的框架，并结合早期试验的定量基准，以优先确定可转化的解决方案和未来方向。
展开英文摘要原文
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide, largely because most patients are diagnosed at advanced stages when curative treatment options are limited. Chimeric antigen receptor (CAR) T-cell therapy has produced deep and durable remissions in several B-cell and plasma-cell malignancies, enabling multiple regulatory approvals; however, its clinical translation to solid tumors such as HCC remains challenging due to the highly immunosuppressive tumor microenvironment (TME). This review discusses the major barriers limiting CAR-based cellular therapy in HCC and critically evaluates engineering strategies designed to improve tumor entry, fitness, safety, and durable control. Building on prior syntheses in CROH and other leading journals, we provide an HCC-specific, mechanism-to-design framework with quantitative benchmarks from early trials to prioritize translatable solutions and future directions.
论文信息
- 作者
- Alsubki R
- 单位
- Department of Clinical Laboratory Sciences, Chair of Medical and Molecular Genetics Research, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Saudi Arabia. Electronic address: Ralsubki@ksu.edu.sa.Saudi Arabia
- 文献类型
- 综述
- 期刊
- Critical reviews in oncology/hematology2026 Jun
- 原文标识
- PubMed 41905571 · DOI 10.1016/j.critrevonc.2026.105304